LUND, Sweden, Aug. 11, 2022 /PRNewswire/ -- The California Department of Public Health has granted Immunovia, Inc., the American subsidiary of Immunovia AB (Nasdaq :IMMNOV) (Stockholm: IMMNOV), a Clinical and Public Health Laboratory license, allowing physicians in California to order the IMMray PanCan-d test for their patients.

"People at risk for pancreatic cancer need better tools for early detection. We are thrilled that this approval enables us to make IMMray PanCan-d available to clinicians in California who care for those at risk." says Jeff Borcherding, Chief Executive Officer of Immunovia, Inc.

For more information, please contact:

Philipp Mathieu

CEO and President

Email: philipp.mathieu@immunovia.com

Karin Almqvist Liwendahl

Chief Financial Officer

Email: karin.almqvist.liwendahl@immunovia.com

The information was submitted for publication on August 10, 2022, at 09:55 am CET.

About Immunovia

Immunovia AB is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer.

Our first product, IMMray™ PanCan-d is the only blood test currently available specifically for the early detection of pancreatic cancer. The test has unmatched clinical performance. Commercialization of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see: www.immunoviainc.com.

Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups globally to make this test available to all high-risk pancreatic cancer groups. 

The USA, the first market in which IMMray™ PanCan-d is commercially available, is the world's largest market for the detection of pancreatic cancer with an estimated value of more than USD 4 billion annually.

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com. 

 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/immunovia-ab/r/immunovia--inc--issued-clinical-and-public-health-laboratory-license-from-california-dept-of-public-,c3612734

The following files are available for download:

https://mb.cision.com/Main/13121/3612734/1613663.pdf

Press release (PDF)

Cision View original content:https://www.prnewswire.com/news-releases/immunovia-inc-issued-clinical-and-public-health-laboratory-license-from-california-dept-of-public-health-for-immray-pancan-d-test-301604178.html

SOURCE Immunovia AB

Copyright 2022 PR Newswire

Immunovia Ab (publ) (LSE:0G8X)
Gráfica de Acción Histórica
De Sep 2022 a Oct 2022 Haga Click aquí para más Gráficas Immunovia Ab (publ).
Immunovia Ab (publ) (LSE:0G8X)
Gráfica de Acción Histórica
De Oct 2021 a Oct 2022 Haga Click aquí para más Gráficas Immunovia Ab (publ).